Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
HKG: 2186
Luye Pharma’s CD25 Monoclonal Antibody BA1106 Gains NMPA Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Luye Pharma’s Goserelin Acetate Injectable Accepted for Breast Cancer Review
China-based Luye Pharma Group (HKG: 2186) announced that another market filing for its goserelin acetate...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...
Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...
Luye Pharma’s Lurbinectedin Receives Hainan Approval for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) announced approval from the Hainan Medical Products Administration for...
Luye Pharma Initiates Phase III Study of Trulicity Biosimilar BA5101 in China
China-based Luye Pharma Group (HKG: 2186) announced the initiation of a Phase III clinical study...
Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico
Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...